Article Sidebar
Views pdf: 43
RELATION BETWEEN CHARACTERISTICS OF CONCURRENT CHEMORADIOTHERAPY AND SURVIVAL IN LUNG ADENOCARCINOMA PATIENTS WITH STAGE IIIB, IIIC AT VIET TIEP HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the relation betwwen characteristics of concurrent chemoradiotherapy and survival in lung adenocarcinoma patients with stage IIIB and IIIC at Viet Tiep Hospital. Subjects and methods: A prospective study with intervention and longitudinal follow-up on 55 lung adenocarcinoma patients with stage IIIB and IIIC treated with concurrent chemoradiotherapy by paclitaxel - carboplatin regimen from October 2020 to September 2024. Results: The average overall and progression-free survival were 29.2 ± 3.2 months and 12.3 ± 1.1 months. Patients receiving radiotherapy with total dose ≥ 60 Gy had longer overall and progression-free survival than patients receiving radiotherapy with total dose < 60 Gy (p < 0.05). Patients receiving chemotherapy for ≥ 6 cycles had a longer overall survival than the group of patients receiving chemotherapy for < 6 cycles (p < 0.05). The group of patients who received a full course of concurrent chemotherapy had longer overall and progression-free survival clearly than the group of patients who did not receive enough therapy (p < 0.01). Conclusions: Treating a full course of concurrent chemoradiotherapy with total dose ≥ 60 Gy improves overall and progression-free survival in adenocarcinoma lung cancer patients with stage IIIB and IIIC.
Article Details
Keywords
Concurrent chemoradiotherapy, Lung cancer, Overall and progression-free survival
References
2. Wood D.E. and Ettinger D.S. (2022), "Non - small cell lung cancer, NCCN Clinical Practice Guildeline in Oncology", doi: https://doi.org/10.6004/jnccn.2022.0025.
3. Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏ (2018), Bộ Y tế, 2018.
4. Hàng Quốc Tuấn (2021), Ung thư phổi không tế vào nhỏ giai đoạn III không mổ được điều trị bằng phác đồ paclitaxel và carboplatin kết hợp hóa xạ đồng thời, Luận án Tiến sĩ Y học, Đại học Y Hà Nội.
5. Chandra B.P., Hak C., Phil B., et al. (2005), "Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non–small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol," Journal of clinical oncology, vol. 23 (25): 5883-5891.
6. Stinchcombe T.E., Hodgson L., Herndon J.E. II, et al. (2009), "Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer," J Thorac Oncol, vol. 4 (9): 1117-1125.
7. Steuer C.E., Behera M., Ernani V., et al (2017), "Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer: A Systematic Review," JAMA Oncol, vol. 3 (8): 1120-1129.
8. Aupérin A., Le Péchoux C., Rolland E., et al. (2010, "Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer," Journal of clinical oncology, vol. 28 (13): 2181-2190.